Coronary vasospasm-induced ventricular tachyarrhythmias.

David J. D'agate,Richard H. Schwartz,J. Lazar

2002-10-01

Abstract:Coronary artery spasm has been shown to play an important role in the pathogenesis of not only variant angina but also various arrhythmias. We present a case report of coronary vasospasm-induced arrhythmia and review the prevalence, mechanism, prognosis and management of this problem.

What problem does this paper attempt to address?

Abstract P2-09-03: Spectrum, Prevalence and Clinical Outcomes of Germline Mutations in PALB2 Genes in 16501 Unselected BRCA1/2-negative Breast Cancer Patients: A Multi-Center Analysis

Jiaojiao Zhou,Honglian Wang,Fangmeng Fu,Zhanwen Li,Yun Liu,Qingjian Feng,Weizhu Wu,Hongxia Wang,Chuan Wang,Yiding Chen

DOI: https://doi.org/10.1158/1538-7445.sabcs19-p2-09-03

IF: 11.2

2020-01-01

Cancer Research

Abstract:Abstract Background: PALB2 (Partner and Localizer of BRCA2) is a breast cancer predisposition gene, which plays a critical role in homologous recombination via interacting with BRCA1/2 and RAD51 when DNA break. However, the clinical relevance of PALB2 germline mutations in Chinese breast cancer patients remains unknown. We attempted to illustrate the full prevalence and spectrum of PALB2 germline mutations in Chinese breast cancer population, and to investigate the clinical outcomes of PALB2 germline mutations. Patients and methods: A total of 21216 unselected breast cancer patients were enrolled from multiple clinical centers in China. After evaluation of the DNA quality and clinical information, 16501 eligible BRCA1/2-negative breast cancer patients were analyzed. A group of 5890 Chinese women without cancer was enrolled as healthy controls. PALB2 screening was based on next-generation sequencing, by screening complete coding sequence and intron-exon boundaries of PALB2. Clinical information was synchronously collected. Results: The 79 PALB2 deleterious germline mutations included 25 nonsense mutations, 47 frameshift mutations, and 7 splicing mutations. The hotspot region for PALB2 mutations was exon4. A total of 41 novel mutations were identified in PALB2. Among the 16501 BRCA1/2-negative breast cancer patients and 5890 healthy women, PALB2 deleterious mutation carriers account for 0.97% (n=160) and 0.19% (n=11) separately. PALB2 mutations were significantly associated with increased breast cancer risk (OR: 5.23, 95% CI 2.89-9.49; P<0.0001), and especially in women aged 30 or younger (OR: 11.97, 95% CI 3.76-34.39; P<0.0001). PALB2 mutation carriers were significantly more likely to be triple negative breast cancers and have bigger tumors, positive axillary lymph nodes, bilateral breast cancers, family history of breast and/or ovarian cancer and family history of any other cancer, than noncarriers. Conclusions: The PALB2 mutations confer a moderately increased breast cancer risk in women, but relatively highly increased breast cancer risk in those aged 30 or younger. PALB2 mutation status is associated with distinct clinical characteristics in breast cancer. Key words:PALB2, breast cancer, germline mutations, next-generation sequencing Citation Format: Jiaojiao Zhou, Honglian Wang, Fangmeng Fu, Zhanwen Li, Yun Liu, Qingjian Feng, Weizhu Wu, Hongxia Wang, Chuan Wang, Yiding Chen. Spectrum, prevalence and clinical outcomes of germline mutations in PALB2 genes in 16501 unselected BRCA1/2-negative breast cancer patients: A multi-center analysis [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-09-03.
Use of comprehensive next-generation sequencing to identify pathogenic germline variants with therapeutic relevance in metastatic breast cancer.

Nicole Margo Grogan,Yi-Mi Wu,Dan R. Robinson,James M. Rae,Norah Lynn Henry,Daniel F. Hayes,Michelle F. Jacobs,Kara J. Milliron,Bailey Hulswit,Lauren E. Hipp,Sofia Merajver,Elena Martinez Stoffel,Arul Chinnaiyan,Erin Frances Cobain

DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.10527

IF: 45.3

2021-05-20

Journal of Clinical Oncology

Abstract:10527 Background: Among patients with early-stage breast cancer, approximately 6-10% have a pathogenic germline variant (PGV) conferring inherited cancer predisposition. In contrast, few studies have explored the frequency and types of PGVs identified in patients with metastatic breast cancer (MBC); therefore, additional data is needed. Methods: From 2011-2020, 278 patients with MBC underwent fresh tumor biopsy and blood sample collection for paired tumor/normal DNA (targeted exome capture with analysis of 1700 genes) and RNA (tumor transcriptome) sequencing through the Michigan Oncology Sequencing (Mi-ONCOSEQ) program. Somatic and germline alterations were annotated and classified according to degree of clinical actionability with results returned to treating oncologists. Retrospective chart review was performed to determine if: 1) a PGV was identified prior to Mi-ONCOSEQ testing, 2) patients met National Comprehensive Cancer Network (NCCN) guideline criteria for genetic testing on the basis of personal or family cancer history and 3) patients received subsequent therapy informed by a PGV. Results: Forty-eight of the 278 patients (17.3%) had at least one PGV identified, with a total of 50 PGVs identified in this cohort. Only twelve of these PGVs (24%) had been identified prior to Mi-ONCOSEQ testing. The most frequent PGVs identified were in CHEK 2 (n = 9, 18%), MUTYH (n = 6, 12%), BRCA 1 (n = 5, 10%), BRCA2 (n = 5, 10%), ATM (n = 4, 8%) and PALB2 (n = 4, 8%). Somatic loss of heterozygosity events (LOH) occurred in 30 of the 50 cases with PGVs identified (60%). LOH events were observed in 83.3% of BRCA1, BRCA2, ATM and PALB2 PGVs, but were less frequently observed with CHEK2 (33.3%) and MUTYH (66.7%). Two hundred sixteen out of 278 patients (77.7%) in this cohort met NCCN criteria for genetic testing, although six patients with a PGV identified (CHEK2: n = 5; MUTYH: n = 1) did not meet NCCN criteria. Twenty-nine PGVs identified (58%) had potential therapeutic relevance and 11 patients (22.9%) received targeted therapy based on the PGV. Conclusions: The frequency of PGVs identified in this cohort is nearly double the frequency reported for patients with early-stage disease, suggesting that certain PGVs may confer worse prognosis. CHEK2, the most frequently identified PGV, was less likely to have an identifiable LOH event. The direct role of CHEK2 PGVs in tumor pathogenesis is uncertain, but other mechanisms of silencing the wild type allele must be considered. Despite the majority of patients meeting NCCN criteria for genetic testing, those with PGVs in CHEK2 were less reliably identified by this mechanism. The majority of PGVs identified were of potential therapeutic relevance, supporting the recommendation for genetic testing in all patients with MBC.

oncology
Therapeutic Implications of Germline Testing in Patients With Advanced Cancers

Zsofia K Stadler,Anna Maio,Debyani Chakravarty,Yelena Kemel,Margaret Sheehan,Erin Salo-Mullen,Kaitlyn Tkachuk,Christopher J Fong,Bastien Nguyen,Amanda Erakky,Karen Cadoo,Ying Liu,Maria I Carlo,Alicia Latham,Hongxin Zhang,Ritika Kundra,Shaleigh Smith,Jesse Galle,Carol Aghajanian,Nadeem Abu-Rustum,Anna Varghese,Eileen M O'Reilly,Michael Morris,Wassim Abida,Michael Walsh,Alexander Drilon,Gowtham Jayakumaran,Ahmet Zehir,Marc Ladanyi,Ozge Ceyhan-Birsoy,David B Solit,Nikolaus Schultz,Michael F Berger,Diana Mandelker,Luis A Diaz Jr,Kenneth Offit,Mark E Robson

DOI: https://doi.org/10.1200/JCO.20.03661

2021-08-20

Abstract:Purpose: Tumor mutational profiling is increasingly performed in patients with advanced cancer. We determined the extent to which germline mutation profiling guides therapy selection in patients with advanced cancer. Methods: Patients with cancer undergoing tumor genomic profiling were prospectively consented for germline cancer predisposition gene analysis (2015-2019). In patients harboring germline likely pathogenic or pathogenic (LP/P) alterations, therapeutic actionability was classified using a precision oncology knowledge base. Patients with metastatic or recurrent cancer receiving germline genotype-directed therapy were determined. Results: Among 11,947 patients across > 50 malignancies, 17% (n = 2,037) harbored a germline LP/P variant. By oncology knowledge base classification, 9% (n = 1042) had an LP/P variant in a gene with therapeutic implications (4% level 1; 4% level 3B; < 1% level 4). BRCA1/2 variants accounted for 42% of therapeutically actionable findings, followed by CHEK2 (13%), ATM (12%), mismatch repair genes (11%), and PALB2 (5%). When limited to the 9,079 patients with metastatic or recurrent cancer, 8% (n = 710) harbored level 1 or 3B genetic findings and 3.2% (n = 289) received germline genotype-directed therapy. Germline genotype-directed therapy was received by 61% and 18% of metastatic cancer patients with level 1 and level 3B findings, respectively, and by 54% of BRCA1/2, 75% of mismatch repair, 43% of PALB2, 35% of RAD51C/D, 24% of BRIP1, and 19% of ATM carriers. Of BRCA1/2 patients receiving a poly(ADP-ribose) polymerase inhibitor, 45% (84 of 188) had tumors other than breast or ovarian cancer, wherein the drug, at time of delivery, was delivered in an investigational setting. Conclusion: In a pan-cancer analysis, 8% of patients with advanced cancer harbored a germline variant with therapeutic actionability with 40% of these patients receiving germline genotype-directed treatment. Germline sequence analysis is additive to tumor sequence analysis for therapy selection and should be considered for all patients with advanced cancer.
Abstract PS10-04: The Landscape of Somatic Genetic Alterations in Breast Cancers from Carriers of Germline Pathogenic Variants in DNA-repair Genes

Minxuan Huang,Melissa Stoppler

DOI: https://doi.org/10.1158/1538-7445.sabcs23-ps10-04

IF: 11.2

2024-05-02

Cancer Research

Abstract:Abstract Background: Hereditary breast cancer in carriers of germline pathogenic or likely pathogenic variants (PVs) in ATM, BRCA1, BRCA2, CHEK2, and PALB2 have unique clinicopathological characteristics compared to sporadic breast cancer. However, very little is known about the underlying differences in somatic genetic alterations between hereditary and sporadic breast cancer. Methods: The study included 7,533 individuals with breast cancer subjected to Tempus xT tumor-normal matched sequencing (596-648 genes). The frequencies of the somatic genetic alterations in each gene were compared separately between tumors arising in individuals with incidental germline PVs (gATM, gBRCA1, gBRCA2, gCHEK2, gPALB2) and sporadic breast tumors. Sporadic tumors were identified as individuals with no detected incidental germline PVs in these 5 genes. Comparisons were made by either Pearson’s Chi-squared or Fisher’s exact test, with false discovery rate (FDR) correction for multiple testing. Breast cancer subtype was determined based on the record of IHC positivity for ER, PR, or HER2. Detection of ERBB2 (HER2) gene amplifications via DNA sequencing was also used to classify samples as HER2+ in the absence of available IHC data. Results: The median age at breast cancer diagnosis for the cohort was 56 years. More than two-thirds of the patients were White (73%) while 14% identified as Black or African American. The overall frequency of incidental germline PVs in each gene was 0.8% for gATM, 1.4% for gBRCA1, 2.1% for gBRCA2, 1.0% for CHEK2, and 0.7% for PALB2. A total of 3,648 (48.4%) tumors were ER+/PR+/HER2-, 1,297 (17.2%) were triple-negative (TNBC), 841 (11.2%) were HER2+ and 1,747 (23.2%) could not be classified due to missing ER, PR or HER2 status, or absence of detected ERBB2 amplifications. Among ER+/PR+/HER2- breast cancers, compared to sporadic tumors, ESR1 mutations were significantly enriched in gATM carriers (33% vs. 11%, q-value 0.05), TP53 alterations were significantly enriched in gBRCA1 PV carriers (69% vs. 30%, q-value < 0.001) but depleted in gATM (12% vs. 30%, q-value 0.4) and gCHEK2 PV carriers (5.4% vs. 30%, q-value 0.06), and PIK3CA (14% vs. 35%, q-value 0.001) and CCND1 (3.4% vs. 17%, q-value 0.02) alterations were significantly lower in gBRCA2 PV carriers. Among TNBC, TP53 alterations were also significantly higher in gBRCA1 PV carriers compared to sporadic tumors (96% vs. 69%, q-value 0.004). In HER2+ breast cancers, ERBB2 alterations were observed in approximately two-thirds of the tumors, and a significant difference was not observed between incidental hereditary and sporadic tumors. Among ER+/PR+/HER2- tumors, although not statistically significant, the frequency of ESR1 (3.1% vs. 11%, q-value >0.9), PIK3CA (12% vs. 35%, q-value 0.2) alterations were lower in incidental gBRCA1 versus sporadic tumors, FGFR1 alterations were lower in incidental gBRCA1 (6.2% vs. 13%, q-value >0.9) and incidental gBRCA2 (3.4% vs. 13%, q-value 0.13) but enriched in incidental gATM (33% vs. 13%, q-value 0.05). Conclusions: The observed differences in the frequencies of CCND1, ESR1, PIK3CA, TP53, and other key genetic alterations between incidental hereditary and sporadic breast cancer highlight the unique tumor biology of breast cancer in germline PV carriers and have significant implications for understanding tumorigenesis and identifying therapeutic strategies for the management of hereditary breast cancer. Citation Format: Minxuan Huang, Melissa Stoppler. The Landscape of Somatic Genetic Alterations in Breast Cancers from Carriers of Germline Pathogenic Variants in DNA-repair Genes [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PS10-04.

oncology
Abstract 977: Germline BRCA1/2 mutations detected by circulating tumor DNA testing in breast cancer patients: A retrospective mutiinstitutional analysis

Letizia Pontolillo,Carolina Reduzzi,Andrew A. Davis,Arielle J. Medford,Annika Putur,Lorenzo Gerratana,Katherine Clifton,Whitney L. Hensing,Marko Velimirovic,Surbhi Warrior,Mara S. Serafini,Eleonora Nicolò,Laura Munoz-Arcos,Jeannine Donahue,Charles S. Dai,Jennifer C. Keenan,Amir Behdad,William J. Gradishar,Diana Giannarelli,Emilio Bria,Cynthia X. Ma,Aditya Bardia,Massimo Cristofanilli

DOI: https://doi.org/10.1158/1538-7445.am2024-977

IF: 11.2

2024-03-23

Cancer Research

Abstract:Background: The use of circulating tumor (ct) DNA testing allows to detect resistant and actionable somatic alterations and it could be associated with the incidental identification of germline mutations. An univocal variant allele frequency (VAF) threshold to distinguish germinal form somatic mutations has not been assessed yet. We aimed to correlate BRCA1/2 ctdNA detected mutations with germline mutational status to determine potential VAF cutoff. Materials and methods:We retrospectively analyzed the incidence of both somatic (s) and germinal (g) BRCA1/2 alterations in a multiinstitutional retrospective breast cancer (BC) cohort to assess the VAF threshold for the likelihood of germline mutations' detection by ctDNA next-generation sequencing (Guardant 360) testing. Clinical variables were analyzed using descriptive analyses and receiving operating characteristic (ROC) curves were generated to determine the VAF cutoff. Results: Two hundred and fourteen patients (pts) with sBRCA1/2 mutations (including variant of uncertain significant and synonymous) detected by ctDNA testing, referred to the enrolling centers between January 2015 to May 2023 were included in the analysis. The median age at diagnosis was 50 years old (Interquartile range (IQR)43,5-61.5), 43% had a family history of cancer. Hormone receptor positive/HER2 negative was the most represented subtype (68%) followed by the HER2 positive (16%) and triple negative (16%) ones. At ctDNA baseline, 95.8% of pts had a metastatic disease; the main sites of metastases were bone (67.4%) and visceral (59.3%). Ninetyfour (43.9%) and 137 (64%) pts had a sBRCA1 and sBRCA2 alterations respectively, while 17 (7.9%) had a co-mutation in BRCA1 and BRCA2. The mean VAF value for sBRCA1 alterations was 10.1% (standard deviation (SD) 19.5%, range [0.04%-84.3%]) while for sBRCA2 alterations was 10.8% (SD 18.9%, range [0.21%-80.3%]). The germinal testing, performed per standard of care, was available for 100 pts (46.7%). Among these, 42 (42%) had at least a pathogenic variant detected. A gBRCA1 mutation was present in 11 (11%) pts while 25 (25%) had a gBRCA2 mutation. Comparing the somatic and germinal testing, 9/100 pts had a concordance for BRCA1 detection, the 2 discordant cases had both a low allele frequency sBRCA2 alterations; the concordance for BRCA2 detection was instead 100%. An optimal cutoff of 38.4% (AUC 0.98) for BRCA1 and 19.5% (AUC 0.96) for BRCA2 was assessed by ROC analysis as the likelihood of a germline meaning of a somatic mutation detected by ctDNA analysis. Conclusion: The identification of BRCA1/2 alterations in ctDNA could guide the use of germline testing. The VAF cutoff identified for the likelihood of a germinal mutation is lower than expected, suggesting that a wider population should be screened for germinal mutation with relevant impact on the therapeutic choices and family screening. Citation Format: Letizia Pontolillo, Carolina Reduzzi, Andrew A. Davis, Arielle J. Medford, Annika Putur, Lorenzo Gerratana, Katherine Clifton, Whitney L. Hensing, Marko Velimirovic, Surbhi Warrior, Mara S. Serafini, Eleonora Nicolò, Laura Munoz-Arcos, Jeannine Donahue, Charles S. Dai, Jennifer C. Keenan, Amir Behdad, William J. Gradishar, Diana Giannarelli, Emilio Bria, Cynthia X. Ma, Aditya Bardia, Massimo Cristofanilli. Germline BRCA1/2 mutations detected by circulating tumor DNA testing in breast cancer patients: A retrospective mutiinstitutional analysis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 977.

oncology
Increased TP53 somatic evolution in peritoneal washes of individuals with BRCA1 germline mutations

Xin Ray Tee,Emma Hazard,Elena Latorre-Esteves,Brendan F Kohrn,Talayeh S Ghezelayagh,Jeanne Uy Fredrickson,CoohleenAnn Coombes,Marc R Radke,Enna Manhardt,Ronit Katz,T Rinda Soong,Elizabeth M Swisher,Barbara M Norquist,Rosa Ana Risques

DOI: https://doi.org/10.1016/j.ygyno.2024.07.690

Abstract:Background: Individuals with germline BRCA1 and BRCA2 pathogenic variants (BRCA carriers) are at high risk of developing high grade serous ovarian carcinoma (HGSC). HGSC is predominantly driven by TP53 mutations, but mutations in this gene are also commonly found in non-cancerous tissue as a feature of normal human aging. We hypothesized that HGSC predisposition in BRCA carriers may be related to increased TP53 somatic evolution, which could be detectable by ultra-deep sequencing of TP53 mutations in gynecological liquid biopsies. Methods: Duplex sequencing was used to identify TP53 mutations with high sensitivity in peritoneal washes and cervical liquid-based cytology (LBC) collected at surgery from 60 individuals including BRCA1 and BRCA2 carriers, and non-carriers. TP53 mutation pathogenicity was compared across groups and with TP53 cancer mutations. Results: TP53 mutations were more abundant in cervical LBC than in peritoneal washes but increased with age in both sample types. In peritoneal washes, but not in cervical LBC, pathogenic TP53 mutation burden was increased in BRCA1 carriers compared to non-carriers, independently of age. Five individuals shared identical pathogenic TP53 mutations in peritoneal washes and cervical LBC, but not in blood. Conclusions: Ultra-deep sequencing of TP53 mutations in peritoneal washes collected at surgery reveals increased burden of pathogenic TP53 mutations in BRCA1 carriers. This excess of pathogenic TP53 mutations might be linked to the elevated risk of HGSC in these individuals. In some patients, concordant TP53 mutations were found in peritoneal washes and cervical LBCs, but the cell of origin remains unknown and deserves further investigation.
Abstract P3-07-02: Identification of potential germline variants (GV) on tumor comprehensive genomic profiling (CGP) in patients with advanced breast cancer (BC): BRCA1/2 and beyond

Marni B Tierno,Kali C Dougherty,Erica Gornstein,Dean C Pavlick,Alexa Schrock,Geoff R Oxnard

DOI: https://doi.org/10.1158/1538-7445.sabcs21-p3-07-02

IF: 11.2

2022-02-15

Cancer Research

Abstract:Abstract Background Detection of pathogenic GVs in patients with BC has implications for both patients and their family members. Management options such as increased surveillance, chemoprevention, and surgical prophylaxis are available to GV carriers. Beyond BRCA1/2, GVs in the cancer susceptibility genes (CSGs) PALB2, ATM, and CHEK2 confer a 2-11-fold lifetime risk of BC. One opportunity CGP assays present is the potential to detect clinically-relevant GVs in addition to targetable somatic variants. While the Breast Cancer Association Consortium found that 5.2% of women with BC carried a GV in one of these five CSGs, we sought to describe the frequency of these potential GVs detected by CGP in a cohort of patients with advanced disease. Methods We reviewed an internal database of patients with advanced BC who underwent testing with a CGP panel using tissue (n= 20,109, FoundationOne® CDx) or plasma (n= 4,182, FoundationOne®Liquid CDx or FoundationOne®Liquid). Cases with a potential GV were identified by filtering base substitutions and short indels for inclusion in ClinVar as pathogenic or likely pathogenic and by variant allele frequency (VAF) based on an optimized assay-specific threshold, focusing on the select CSGs of BRCA1/2, PALB2, ATM and CHEK2. To enable follow-up of potential GVs, we implemented a new reporting “banner” to highlight select short variants in these CSGs. Predominant patient ancestry was inferred using a SNP-based classifier and Fisher’s exact test was utilized for comparison between groups. Results A total of 24,291 unique patients with primarily advanced BC had CGP results available for study, with common actionable findings including PIK3CA mutations (8,572, 35.3%), ESR1 mutations (3,289, 13.5%), and HER2 amplification (1,602, 6.6%). Focusing on the 5 CSGs, 16.4% of patients (3,986) had at least one pathogenic alteration detected in BRCA2 (1,153, 4.7%), ATM (969, 4.0%), CHEK2 (982, 4.0%) BRCA1 (849, 3.5%) or PALB2 (308, 1.3%); 1.1% of patients (263) harbored alterations in multiple CSGs. 50.7% (2,020/3,986) of patients with pathogenic alterations in these CSGs - 8.3% (2,020/24,291) of total patients with advanced BC - had an alteration meeting criterion as a potential GV. Variants in BRCA1 (511/919, 55.6%), BRCA2 (786/1,425, 55.2%), and PALB2 (201/376, 53.5%), more frequently met criteria as potential GVs than variants in CHEK2 (328/1,046, 31.4%) or ATM (265/1,100, 24.1%). In these five CSGs, 1,796/3,195 alterations detected on tissue CGP (56.2%) and 295/1,671 detected in plasma (17.7%) met criteria as a potential GVs. Ancestry analysis of 20,108 assessable BC patients tested using tissue CGP showed potential GVs in CHEK2 were more common in European vs non-European (1.7% vs 0.4%, p<0.01) and potential GVs in PALB2 were more common in African vs non-African (1.4% vs 0.7%, p<0.01) ancestries. Of 1,961 patients with BC tested over a 2-month period, 9.7% of reports (191) included a germline banner reporting a potential GV in one of these 5 CSGs and recommending consideration of referral for germline testing. Conclusion Potential pathogenic GVs in BRCA1/2, PALB2, ATM and CHEK2 were identified in 8.3% of patients with advanced BC tested utilizing CGP when filtering by VAF and ClinVar annotation. Highlighting these potential GVs with a report banner provides the opportunity for follow-up germline testing and genetic counseling for patients who otherwise may not have been referred for additional testing. These alterations were detected in both tissue and plasma CGP and in patients of varying ancestries. The potential for detection of potential GVs plus the detection of actionable driver and resistance mechanisms may add to the clinical value of CGP for patients with breast cancer. Citation Format: Marni B Tierno, Kali C Dougherty, Erica Gornstein, Dean C Pavlick, Alexa Schrock, Geoff R Oxnard. Identification of potential germline variants (GV) on tumor comprehensive genomic profiling (CGP) in patients with advanced breast cancer (BC): BRCA1/2 and beyond [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-07-02.

oncology
DENSITY‐DEPENDENT SEXUAL SELECTION IN THE FUNGUS BEETLE, BOLITOTHERUS CORNUTUS

J. Conner

DOI: https://doi.org/10.1111/j.1558-5646.1989.tb02589.x

1989-11-01

Evolution; international journal of organic evolution

Abstract:The hypothesis that population density can affect sexual selection on male horn size was tested in a three‐year study of a fungus beetle, Bolitotherus cornutus. Males of this species have horns that vary greatly in length. These horns are used in fights over females; longer‐horned males win the majority of fights, regardless of population density. However, density does affect the relationship between horn length and access to females. In six populations of naturally and experimentally varying densities, longer‐horned males gained a greater advantage in access to females in low‐density populations than at high density. This increase in access to females causes an increase in the number of females inseminated by longer‐horned males; thus, sexual selection for longer horns is stronger at lower densities.
Abstract 5872: Investigation on the Prevalence of Germline and Somatic Mutations in Gynecological Malignancies: Implications for Risk Assessment and Therapeutic Decision-Making

Hao Wen,Qin Xu,Xiujie Sheng,Huawen Li,Xipeng Wang,Xiaohua Wu

DOI: https://doi.org/10.1158/1538-7445.am2022-5872

IF: 11.2

2022-01-01

Cancer Research

Abstract:Introduction: Heritable mutations in cancer predisposition genes increase the relative risk of developing malignant gynecological tumors, whereas actionable somatic mutations could serve as biomarker for therapeutic decision-making. Our study explored the prevalence of germline pathogenic/likely-pathogenic (P/LP) mutations and actionable somatic mutations to understand the clinical utility of next-generation sequencing (NGS) in gynecological malignancies. Methods: Genomic data was retrospectively analyzed for 1,610 women with various stages of gynecological malignancies including ovarian (OC, n=945), cervical (CC, n=358), and endometrial cancers (EC, n=307). Genomic data were derived from targeted NGS of paired white blood cell and other biological samples using a 520-gene panel that included 62 cancer predisposition genes. Genomic signatures including tissue-based tumor mutation burden (tTMB) and microsatellite instability (MSI) were also estimated from somatic mutation profiles. Results: The prevalence of germline P/LP mutations in cancer predisposition genes was 20.6% for OC, 13.4% for EC, and 6.4% for CC. OC had the highest mutation rate in genes involved in the homologous recombination repair pathway (18.8%, 178/945), while EC had the highest mutation rate in genes involved in mismatch repair (MMR) pathway (5.5%, 17/307). The frequency of actionable germline P/LP mutations was 19.8% for OC, 11.7% for EC, and 5.0% for CC. The detection rate for actionable somatic mutations were comparable between carrier and non-carrier of germline mutations (OC, 80.5% vs 76.3%, p=0.2; EC, 73.2% vs 80.5%, p=0.4; and CC, 56.5% vs 63.0%, p=0.7). tTMB was also comparable and generally low among carrier and non-carrier of germline mutations (OC, 3.0 [range: 2.0-5.0] vs 3.0 [2.0-5.0], p=0.9; EC, 6.2 [4.8-45.1] vs. 4.8 [2.8-13.2], p=0.1; and CC, 4.8 [2.4-6.0] vs 4.0 [2.4-7.9], p=0.8). The proportion of MSI-H was comparable for OC patients with or without germline mutations (2.6% vs 1.2%, p=0.2); however, the proportion of MSI-H was significantly higher for EC (29.3% vs 11.7%, p=0.019) and CC (13.0% vs 1.2%, p<0.001) who were carriers of germline mutations than non-carriers. The proportion of MSI-H was comparable between EC patients with germline (n=5) and somatic (n=29) MMR gene mutations (40.0%, 2/5 vs 48.3%, 14/29; p=1). EC patients with MSI-H were more likely to have high tTMB (cut-off ≥7 mutations/Mb) (p<0.001). Conclusions: The comparable frequency of actionable somatic mutations in women with or without germline mutations indicates that both populations could benefit from NGS testing. Our findings raise the importance of NGS-based genetic testing with a large gene panel as part of gynecological cancer screening and diagnosis to explore heritable and acquired mutation status for risk assessment and therapeutic decision-making. Citation Format: Hao Wen, Qin Xu, Xiujie Sheng, Huawen Li, Xipeng Wang, Xiaohua Wu. Investigation on the prevalence of germline and somatic mutations in gynecological malignancies: Implications for risk assessment and therapeutic decision-making [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5872.
Abstract PS16-08: Germline Mutation Landscape in Chinese Breast Cancer Patients

Nan Wang,Jiayang Zhang,Lu Tan,Hao Liao,Yaxin Liu,Xinyu Gui,Jiaxin Niu,Feng Xie,Yue Zhang,Yong Huang,Jianjun Yu,Huiping Li

DOI: https://doi.org/10.1158/1538-7445.sabcs20-ps16-08

IF: 11.2

2021-01-01

Cancer Research

Abstract:Abstract Background: Genetic testing for patients with breast cancer (BCa) patients may change the routine patient care and shift the paradigm towards more personalized managing and treatment strategies. In particular, testing germline mutations in BRCA1/2 has become a part of the standard clinical practice for patients with BCa. However, our understanding of genetic epidemiology of BCa is mainly driven by data from Caucasian populations and it has been evident that gene alterations may be ethnic specific in breast cancer. Methods: Aiming to delineate the landscape of germline mutations in Chinese patients with BCa to breast cancer, we collected blood samples from in 356 BCa patients at stage I-IV in Beijing Cancer Hospital between Jan. 2013 to Dec. 2019. Peripheral blood mononuclear cells were isolated from blood samples and genomic DNA were extracted for capture-based NGS sequencing. A large comprehensive 600 gene panel (PredicineATLAS, Huidu Medical Science Techonology, Inc.) was used to detect germline mutations in the covered genes with average 300x sequencing depth. Results: A total of 356 BCa patients were included in our study, with the median age at first diagnosis of 49 years (Range: 21-87). Among all cases, 21.9% (78/356, 95% confidence interval [CI]: 17.7-26.6%) carried pathogenic or likely pathogenic mutations in 48 cancer related genes. Twenty-seven patients (7.6%, 95% CI: 5.1-10.8%) harbored BRCA1/2 mutations, followed by 5 patients carrying ATM mutations and RAD50 mutations respectively. Other commonly mutated genes include BARD1 (1.1%), FANCD2 (1.1%), CHEK2 (0.6%), FANCC (0.6%), FANCM (0.6%), PMS2 (0.6%), and TP53 (0.6%), most of which are related to DNA damage repair pathway. Moreover, BRCA1/2 carriers were more likely to appear among those with breast or ovarian cancer family history than those without (OR=3.41, 95% CI: 1.14-9.12, P=0.01). Compared with patients that aged older than 50 years at first diagnosis, those aged 30 years or younger were 6 times more likely to detect germline mutations in BRCA1/2 (95% CI: 1.18-26.1, P=0.02). In addition, mutations in BRCA1/2 were differentially associated with breast cancer subtypes. BRCA1 mutations were strongly enriched in triple-negative breast cancer (TNBC) (OR=6.7, 95% CI: 1.54-33.13, P=0.005). There is no strong significant survival difference observed between BRCA1/2 carriers and non-carriers, however, patients carrying ATM or RAD50 mutations tend to have lower disease-free survival. Conclusions: This is a comprehensive analysis of germline mutation spectrum in a large Chinese patient cohort with breast cancer. Collectively, a substantial proportion of patients with breast cancer had hereditary risk factors. Distinct distribution of pathogenic mutations in breast cancer subtypes and differential associations between mutation status and clinical features were further observed. All these findings will advance our understanding regarding the pathologies and heterogeneity of breast cancer. Citation Format: Nan Wang, Jiayang Zhang, Lu Tan, Hao Liao, Yaxin Liu, Xinyu Gui, Jiaxin Niu, Feng Xie, Yue Zhang, Yong Huang, Jianjun Yu, Huiping Li. Germline mutation landscape in Chinese breast cancer patients [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS16-08.
Perl Simulation of a Job Shop Type Problem

J. Mosterín,D. Fuente,M. Monterrey

Abstract:
Identification and Characterization of Germline Pathogenic Variants Using Matched Tumor-Normal Next-Generation Sequencing in 7363 Pan-Cancer Patients in China

Yuting Yi,Fei Ma,Michael F. Sharpnack,Jun Zhao,Yan-Fang Guan,Pingping Dai,Jiaojiao Huan,Li Liu,Quchang Ouyang,Yidong Zhou,Rongrong Chen,Ling Yang,Xin Yi,David Paul Carbone,Xuefeng Xia,Jinji Yang,Kai He

DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.1545

IF: 45.3

2018-01-01

Journal of Clinical Oncology

Abstract:1545 Background: Comprehensive NGS panel based genetic testing is becoming more common to help clinicians provide personalized cancer care. Matched tumor-normal sequencing is recommended primarily to detect tumor-specific variants. Previously under-explored, it could also detect pathogenic germline alterations in cancer patients. Using targeted matched tumor-normal NGS, we identified and characterized germline variants in a large pan-cancer patient cohort in China. Methods: We surveyed the germline variants in 7363 Chinese patients across more than 18 diverse cancer types. Germline variants in 62 cancer-susceptibility genes were called from a 1021 gene NGS panel analyzing matched normal DNA. Following AMCG guidelines, variants were classified into pathogenic, likely pathogenic, variant of unknown significance, likely benign, or benign. Results: 385 germline pathogenic and likely pathogenic variants (GPVs) were identified in 374/7363 (5.1%) patients. Ovarian cancer (27.6%, 37/134) represented the highest prevalence. Breast cancer (11.3%, 92/813), colorectal cancer (8.3%, 66/791), pancreatic cancer (6.2%, 8/130), renal cell cancer (6%, 5/84), and gastric cancer (5.1%, 14/273) displayed relatively high rates of GPVs in line with expectations. Interestingly, NSCLC (2.5%, 88/3572) and hepatocellular cancer (2.3%, 5/214) also showed such events. In total, only 192/385 (49.9%) participants presented with GPVs in cancer-susceptibility genes in the expected cancer types. BRCA2 and BRCA1 were the top two common genes, which were found in 146 patients across 15 cancer types including 27/3572 (1%) NSCLC and 3/214 (1.4%) hepatocellular cancer patients. 285/385 (74%) of the GPVs were actionable for targeted therapy. Conclusions: Germline variants can be identified on routine targeted matched tumor-normal NGS and commonly exist in patients with cancers of diverse tissue origin. Recognition of germline variants may be valuable in therapeutic interventions and genetic risk analysis. We are currently performing retrospective family history analysis and genetic counseling for those patients with unreported GPVs.
Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients.

Jie Sun,Hua Meng,Lu Yao,Meng Lv,Jian Bai,Jianguang Zhang,Lientu Wang,Tao Ouyang,Jinfeng Li,Tianfeng Wang,Zhaoqing Fan,Tie Fan,Benyao Lin,Yuntao Xie

DOI: https://doi.org/10.1158/1078-0432.ccr-16-3227

IF: 13.801

2017-01-01

Clinical Cancer Research

Abstract:Abstract Purpose: The prevalence of mutations in cancer susceptibility genes such as BRCA1 and BRCA2 and other cancer susceptibility genes and their clinical relevance are largely unknown among a large series of unselected breast cancer patients in the Chinese population. Experimental Design: A total of 8,085 consecutive unselected Chinese breast cancer patients were enrolled. Germline mutations in 46 cancer susceptibility genes were detected using a 62-gene panel. Results: Pathogenic mutations were identified in 9.2% of patients among the 8,085 unselected breast cancer patients. Of these, 5.3% of patients carried a BRCA1 or BRCA2 mutation (1.8% in BRCA1 and 3.5% in BRCA2), 2.9% carried other breast cancer susceptibility genes (BOCG) and 1.0% carried another cancer susceptibility genes. Triple-negative breast cancers had the highest prevalence of BRCA1/2 mutations (11.2%) and other BOCG mutations (3.8%) among the four molecular subgroups, whereas ER−/PR−HER2+ breast cancers had the lowest mutations in BRCA1/2 (1.8%) and BOCG (1.6%). In addition, BRCA1 mutation carriers had a significant worse disease-free survival [unadjusted hazard ratio (HR) 1.60; 95% confidence interval (CI) 1.10–2.34; P = 0.014] and disease-specific survival (unadjusted HR 1.96; 95% CI, 1.03–3.65; P = 0.040) than did non-carriers, whereas no significant difference in survival was found between BRCA2 mutation carriers and non-carriers. Conclusions: 9.2% of breast cancer patients carry a pathogenic mutation in cancer susceptibility genes in this large unselected series. Triple-negative breast cancers have the highest prevalence of mutations in BRCA1 /2 and other breast cancer susceptibility genes among the four molecular subgroups, whereas ER−/PR−HER2+ breast cancers had the lowest mutations in these genes. Clin Cancer Res; 23(20); 6113–9. ©2017 AACR.
Clinical and genetic characterization of cancer patients with multiple germline variants.

Hong Zheng,Min Gao,Weijiao Gao,Nan Zhang,Hongguo Wang,Nan Song,Naiyi Zhang,Wei Wang,Qian Li,Mingming Yuan,Rongrong Chen,Xuefeng Xia,Yunong Gao

DOI: https://doi.org/10.1200/JCO.2021.39.15_suppl.e22523

IF: 45.3

2021-01-01

Journal of Clinical Oncology

Abstract:e22523 Background: Hereditary tumors are generally monogenic diseases with autosomal dominant inheritance. However, we noticed that some individuals may harbor ≥2 germline mutations in one or multiple genes, which remains to be explored. Methods: Genetic mutations were reviewed in more than 50,000 cancer patients who underwent hybridization capture based next-generation sequencing (NGS). Germline variants were interpreted following ACMG guideline, and only pathogenic and likely pathogenic variants were included in this study. Results: Multiple germline variants were identified in 42 individuals with the detection rate of 0.075%. The median age at diagnosis was 48 years (range 31-73). Two thirds of patients were female and 26.2% of patients has cancer family history. Prostate cancer is the most common cancer type (0.6%, 2/332), followed by carcinomas of ovarian or fallopian tube (0.48%, 7/1461), breast (0.24%, 8/3302), pancreas (0.2%, 2/982) and so on. Surprisingly, 7 patients with lung cancer also harbored ≥2 germline mutations (0.02%). Most of these germline variants affected DNA damage repair pathways [75.6% homologous recombination repair (HR), 8.1% mismatch repair (MMR), 1.2% base excision repair (BER)]. Four patients had two germline variants identified on a single gene (2 ATM, 1 BRCA1, 1 BRCA2). Three variants were identified in 2 patients, and 2 variants were identified in the remaining 36 patients. Two or more germline variants in HRR pathway were identified in 64.3% of patients, among which 18.5% patients had BRCA1+ BRCA2 double variants. The efficacy of poly ADP-ribose polymerase inhibitors (PARPi) in this specific population should raise concern. Besides, double variants in HRR and MMR pathway were found in 5 patients, which suggested the potential benefit of immunotherapy and PARPi combination therapy. Conclusions: In addition to identify variants contributing to the personal and family cancer history, NGS can accidentally identify germline variants that may suggest the susceptibility of other hereditary tumors. Multiple variants on HRR or MMR genes may have important implications for the treatment strategy for these patients.
Effect of somatic-germline genomic integration on the contribution of pathogenic germline genetic variants (gPV) to colorectal cancer (CRC) carcinogenesis.

Emily Harrold,Henry S. Walch,Walid Khaled Chatila,Yelena Kemel,Matilde Borio,Anna Maio,Aliya Khurram,Erin E. Salo-Mullen,Alicia Latham,Yonina R. Murciano-Goroff,Kenneth Offit,Neil Howard Segal,Michael Bonner Foote,Leonard B. Saltz,Rona Yaeger,Nikolaus Schultz,Diana Mandelker,Andrea Cercek,Zsofia Kinga Stadler

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.10595

IF: 45.3

2023-06-01

Journal of Clinical Oncology

Abstract:10595 Background: Approximately 14% of CRC patients harbor a germline pathogenic variant (gPV) in a cancer susceptibility gene. As gPV prevalence alone is insufficient evidence for cancer causation, we performed an integrated germline and somatic genomic analysis to discover the extent to which gPVs may be driving CRC carcinogenesis. Methods: Using the MSKCC IMPACT dataset, we identified all patients with CRC who had undergone targeted tumor-normal sequencing (NCT01775072) inclusive of up to 90-genes assessed for germline variants. gPV in tested genes were categorized according to known association with CRC susceptibility and penetrance level. For example, high/moderate penetrance CRC-risk genes included: APC, MLH1, MSH2, MSH6, PMS2, EPCAM, biallelic MUTYH, SMAD4, STK11, BMPR1A, PTEN, POLD1, POLE, TP53. Low-penetrance CRC-risk genes included: monoallelic MUTYH, APC I1307K, CHEK2, BLM. In patients with a gPV, biallelic inactivation at the implicated germline region was inferred based on loss of heterozygosity (LOH) or somatic pathogenic alteration in the tumor. Results: Of 3988 CRC patients, 16.3% (650/3988) harbored at least one gPV (65 patients: 2 gPVs; 3 patients: 3 gPVs). Among a total of 721 gPVs encompassing 55 genes (252 high-penetrance, 118 moderate-penetrance, 351 low/recessive/uncertain-penetrance), overall biallelic inactivation was observed in 41%. In patients with gPVs associated with high/moderate penetrance CRC-risk genes, biallelic inactivation in tumors was present in 70%, while in patients with gPVs in high/moderate penetrance non-CRC genes this was 24% (p = < 0.0001). When assessed according to age at CRC diagnosis, biallelic inactivation in high/moderate penetrance CRC-risk genes was higher in patients diagnosed at age 50 (p = 0.003); no such difference was observed in high/moderate penetrance non-CRC-risk genes. Among non-CRC-risk genes, in the high/moderate penetrance HRD genes, biallelic loss in the tumor was seen in 29% gATM, 54% gBRCA1, 22% gBRCA2, 30% gBRIP1, and 40% of gRAD51C/D positive patients. There was no difference in the rate of biallelic loss by age in patients with gPVs in HRD genes. Biallelic inactivation in tumors in patients with low-penetrance CRC-risk gPVs was 40% versus 14% in patients with low-penetrance non—CRC gPVs (p = < 0.0001). Conclusions: Germline-somatic integration implicated nearly half of all identified gPVs in CRC carcinogenesis. While the highest rate of biallelic inactivation was seen in high/moderate penetrance CRC-risk genes, biallelic inactivation in non-CRC genes, such as the HRD genes, warrants further assessment to discern the contribution of these gPVs to CRC carcinogenesis. Our findings may have implications for novel treatment strategies exploiting these pathways.

oncology
On the Heritability of Geographic Range Sizes

T. J. Webb,K. Gaston

DOI: https://doi.org/10.1086/368296

2003-03-28

Abstract:Within taxonomic groups, most species are restricted in their geographic range sizes, with only a few being widespread. The possibility that species‐level selection on range sizes contributes to the characteristic form of such species–range size distributions has previously been raised. This would require that closely related species have similar range sizes, an indication of “heritability” of range sizes at the species level. Support for this view came from a positive correlation between the range sizes of closely related pairs of fossil mollusc species. We extend this analysis by considering the relationship between the geographic range sizes of 103 pairs of contemporary avian sister species. Range sizes in these sister species show no evidence of being more similar to each other than expected by chance. A reassessment of the mollusc data also suggests that the high correlation was probably overestimated because of the skewed nature of range size data. The fact that sister species tend to have similar life histories and ecologies suggests that any relationship between range sizes and biology is likely to be complicated and will be influenced by historical factors, such as mode of speciation and postspeciation range size transformations.
Clinical syndromes linked to biallelic germline variants in and

Noah C. Helderman,Ting Yang,Claire Palles,Diantha Terlouw,Hailiang Mei,Ruben H.P. Vorderman,Davy Cats,Marcos Díaz Gay,Marjolijn C.J. Jongmans,Ashwin Ramdien,Irma van de Beek,Thomas F. Eleveld,Andrew Green,Frederik J. Hes,Marry M. van den Heuvel-Eibrink,Annelore Van Der Kelen,Sabine Kliesch,Roland P. Kuiper,Inge M.M. Lakeman,Lisa E.E.L.O. Lashley,Leendert H.J. Looijenga,Manon S. Oud,Johanna Steingröver,Yardena Tenenbaum-Rakover,Carli M. Tops,Frank Tüttelmann,Richarda M. de Voer,Dineke Westra,Margot J. Wyrwoll,Mariano Golubicki,Marina Antelo,Laia Bonjoch,Mariona Terradas,Laura Valle,Ludmil B. Alexandrov,Hans Morreau,Tom van Wezel,Sergi Castellví-Bel,Yael Goldberg,Maartje Nielsen

DOI: https://doi.org/10.1101/2024.10.30.24315828

2024-11-04

Abstract:and are newly proposed cancer predisposition genes, linked to polyposis and early–onset cancer, in addition to their association with hypogonadism. Given the uncertain range of phenotypic manifestations and unclear cancer risk estimates, this study aimed to delineate the molecular and clinical characteristics of individuals with biallelic germline / variants. Population allele frequencies and biallelic variant carrier frequencies were calculated using data from gnomAD, and a variant enrichment analysis was conducted across multiple cancer and non–cancer phenotypes using data from the 100K Genomes Project and the 200K exome release of the UK Biobank. A case series was conducted, including previously reported variant carriers with and without updated clinical data and newly identified carriers through the European Reference Network (ERN) initiative for rare genetic tumor risk syndromes (GENTURIS). Additionally, mutational signature analysis was performed on tumor data from our case series and publicly available datasets from the Hartwig Medical Foundation and TCGA Pan–Cancer Atlas to identify mutational signatures potentially associated with MCM8/MCM9 deficiency. Predicted loss of function and missense variants in (1.4 per 100,000 individuals) and (2.5 per 100,000 individuals) were found to be rare in gnomAD. However, biallelic variants showed significant enrichment in cases from the 100K Genomes Project compared to controls for colonic polyps (odds ratio (OR) 6.51, 95% confidence interval (CI) 1.24 – 34.11; = 0.03), rectal polyps (OR 8.40, 95% CI 1.28 – 55.35; = 0.03), and gastric cancer (OR 27.03, 95% CI 2.93 – 248.5; = 0.004). No significant enrichment was found for biallelic variant carriers or in the 200K UK Biobank. In our case series, which included 26 biallelic and 28 biallelic variant carriers, we documented polyposis, gastric cancer, and early–onset colorectal cancer in 6, 1, and 6 biallelic variant carriers, respectively, while these phenotypes were not observed in biallelic variant carriers. Additionally, our case series indicates that, beyond hypogonadism—which was present in 23 and 26 of the carriers, respectively—biallelic and variants are associated with early–onset germ cell tumors (occurring before age 15) in 2 and 1 variant carriers. Tumors from / variant carriers with available germline sequencing data predominantly displayed clock–like mutational processes (single base substitution signatures 1 and 5), with no evidence of signatures associated with DNA repair deficiencies. Our data indicates that biallelic variants are associated with polyposis, gastric cancer, and early–onset CRC, while both biallelic and variants are linked to hypogonadism and the early development of germ cell tumors. These findings underscore the importance of including / in diagnostic gene panels for certain clinical contexts and suggest that biallelic carriers may benefit from cancer surveillance.
A Multi-Institutional Investigation Assessing Prevalence of Germline Genetic Alterations in Chinese Patients with Gastric Carcinoma.

Yinjie Zhang,Xicheng Wang,Changbin Zhu,Xiaotian Zhang,Qing Wei,Lvzhi Ren,Di Shao,Jing Gao,Yan,Jingdong Zhang,Xiao-Bing Chen,Chaojie Wang,Qiu Meng,Xin Wang,Baorui Liu,Lin Shen

DOI: https://doi.org/10.1200/jco.2019.37.15_suppl.e13020

IF: 45.3

2019-01-01

Journal of Clinical Oncology

Abstract:e13020 Background: Gastric carcinoma is one of the most common malignancies in east asian. Previous studies demonstrated around 10% of patients with gastric cancer were found to have pathogenic germline variants. While, predisposition genes of gastric cancer in Chinese patients are still largely unknown. Thus, we aim to delineate prevalence of deleterious germline mutations in Chinese gastric patients with hereditary high-risk familial cancer history. We also aim to analyze clinical relevance of deleterious germline mutations. Methods: Forty index cases were recruited from 7 institutions in China. DNA samples extracted from blood specimens were captured using a 171-cancer predisposition gene panel and then sequenced by MGI-SEQ 2000 platform. Germline variants were determined to be deleterious according to the ACMG 2015 guidelines. Pathogenic and Likely pathogenic germline variants were further validated by Sanger sequencing. Results: 12 of 40 (30%) probands had 13 pathogenic/likely pathogenic germline variants involving 11 different genes: CHEK2 (n = 2), SPINK1 (n = 2), BLM (n = 1), CDH1(n = 1), EXT2 (n = 1), MLH1 (n = 1), MSH2(n = 1), MUTYH (n = 1), PALB2 (n = 1), NF1 (n = 1), ERCC2 (n = 1). For patients with multiple primary cancers, pathogenic germline alterations were exclusively presented (5 out of 12) (P=0.003). Besides,27 germline variants (like EPCAM, RAD54B, FANCD2, FANCA) with uncertain significance in 15 patients were predicated to be deleterious via in silico predictors. Conclusions: This multi-institutional study identified 30% (12/40) of Chinese gastric cancer patients with family history to have deleterious germline alterations. And potential deleterious variants were also identified. Our data illustrates a significantly distinguished spectrum of germline variants compared with Caucasian ones. This may indicate unique carcinogenesis of gastric cancer in Chinese patients. Since patients with pathogenic or likely pathogenic germline variants have dismal clinical outcome and higher rate of multi-cancer occurrence, genetic counseling of gastric cancer should be considered for individuals with family history at their early age.
Abstract P2-09-01: Population-based Risk Estimates of Clinical Subtypes of Breast Cancer among Carriers of Germline Pathogenic Variants in Cancer Predisposition Genes

Siddhartha Yadav,Chunling Hu,Nicholas J. Boddicker,Eric Polley,Steven Hart,Rohan Gnanaolivu,Jie Na,Hongyan Huang,Song Yao,Celine M. Vachon,Lauren Teras,Jack A. Taylor,Dale P. Sandler,Julie R. Palmer,Janet E. Olson,Susan Neuhausen,Elena Martinez,Sara Lindstroem,Loic Le Marchand,Charles Kooperberg,Christopher Haiman,Mia M. Gaudet,James V. Lacey,Kimberly A. Bertrand,Leslie Bernstein,Paul W. Auer,Christine Ambrosone,Jeffrey N. Weitzel,Peter Kraft,David E. Goldgar,Katherine L. Nathanson,Susan M. Domchek,Fergus J. Couch

DOI: https://doi.org/10.1158/1538-7445.sabcs21-p2-09-01

IF: 11.2

2022-01-01

Cancer Research

Abstract:Introduction: The risk of specific clinical subtype of breast cancer (defined by ER and HER2 status) among women in the general population who are carriers of germline pathogenic variants (PVs) in cancer predisposition genes is not well-defined. Methods: A total of 13,153 women with breast cancer (ER+/HER2-: 9381; ER+/HER2+: 1462; ER-/HER2+: 690; and ER-/HER2-: 1620) and 25,005 unaffected women (controls) from nine studies within the CAnceR RIsk Estimates Related to Susceptibility (CARRIERS) consortium that were not enriched for family history or early onset disease were included in the present analysis. A multiplex amplicon-based panel was used to perform germline sequencing for cancer predisposition genes. Case-control associations for each of the four clinical subtype of breast cancer was performed for PVs in 5 common breast cancer predisposition genes (ATM, BRCA1, BRCA2, CHEK2 and PALB2) utilizing a logistic regression model adjusting for study, age at diagnosis, race/ethnicity and family history of breast cancer. Results: The frequency of PVs in 5 genes was 3.8% for ER+/HER2-, 6.2% for ER+/HER2+, 4.2% for ER-/HER2+ and 9.3% for ER-/HER2- subtypes. PVs in BRCA1 and BRCA2 were associated with high risk (Odds Ratio (OR) >4) for all clinical subtypes of breast cancer, but the risk was highest (OR>8) for ER-/HER2- breast cancer. PVs in PALB2 were associated with high risk (OR>4) of ER-/HER2- and ER+/HER2+ subtypes and moderate risk (OR: 2-4) of ER+/HER2- breast cancer. Irrespective of the HER2 status, PVs in ATM were associated with a moderately increased risk (OR: 2-4) of ER+ breast cancer but the risk of ER- breast cancer was not elevated. In contrast, PVs in CHEK2 were associated with high risk (OR>4) of ER+/HER2+ breast cancer and moderate risk (OR: 2-4) of ER+/HER2- and ER-/HER2+ breast cancer, but the risk of ER-/HER2- breast cancer was not elevated. Conclusions: This study provides population-based estimates of risk of specific clinical subtypes of breast cancer which will be useful for genetic counseling and targeting appropriate screening strategies in PV carriers based on subtype specific risks of breast cancer. Citation Format: Siddhartha Yadav, Chunling Hu, Nicholas J. Boddicker, Eric Polley, Steven Hart, Rohan Gnanaolivu, Jie Na, Hongyan Huang, Song Yao, Celine M. Vachon, Lauren Teras, Jack A. Taylor, Dale P. Sandler, Julie R. Palmer, Janet E. Olson, Susan Neuhausen, Elena Martinez, Sara Lindstroem, Loic Le Marchand, Charles Kooperberg, Christopher Haiman, Mia M. Gaudet, James V. Lacey, Kimberly A. Bertrand, Leslie Bernstein, Paul W. Auer, Christine Ambrosone, Jeffrey N. Weitzel, Peter Kraft, David E. Goldgar, Katherine L. Nathanson, Susan M. Domchek, Fergus J. Couch, CARRIERS Consortium. Population-based risk estimates of clinical subtypes of breast cancer among carriers of germline pathogenic variants in cancer predisposition genes [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-09-01.
Multigene Hereditary Cancer Panels Reveal High-Risk Pancreatic Cancer Susceptibility Genes.

Chunling Hu,Holly LaDuca,Hermela Shimelis,Eric C Polley,Jenna Lilyquist,Steven N Hart,Jie Na,Abigail Thomas,Kun Y Lee,Brigette Tippin Davis,Mary Helen Black,Tina Pesaran,David E Goldgar,Jill S Dolinsky,Fergus J Couch

DOI: https://doi.org/10.1200/PO.17.00291

2018-01-01

JCO Precision Oncology

Abstract:PURPOSE:The relevance of inherited pathogenic mutations in cancer predisposition genes in pancreatic cancer is not well understood. We aimed to assess the characteristics of patients with pancreatic cancer referred for hereditary cancer genetic testing and to estimate the risk of pancreatic cancer associated with mutations in panel-based cancer predisposition genes in this high-risk population. METHODS:Patients with pancreatic cancer (N = 1,652) were identified from a 140,000-patient cohort undergoing multigene panel testing of predisposition genes between March 2012 and June 2016. Gene-level mutation frequencies relative to Exome Aggregation Consortium and Genome Aggregation Database reference controls were assessed. RESULTS:The frequency of germline cancer predisposition gene mutations among patients with pancreatic cancer was 20.73%. Mutations in ATM, BRCA2, CDKN2A, MSH2, MSH6, PALB2, and TP53 were associated with high pancreatic cancer risk (odds ratio, > 5), and mutations in BRCA1 were associated with moderate risk (odds ratio, > 2). In a logistic regression model adjusted for age at diagnosis and family history of cancer, ATM and BRCA2 mutations were associated with personal history of breast or pancreatic cancer, whereas PALB2 mutations were associated with family history of breast or pancreatic cancer. CONCLUSION:These findings provide insight into the spectrum of mutations expected in patients with pancreatic cancer referred for cancer predisposition testing. Mutations in eight genes confer high or moderate risk of pancreatic cancer and may prove useful for risk assessment for pancreatic and other cancers. Family and personal histories of breast cancer are strong predictors of germline mutations.

Coronary vasospasm-induced ventricular tachyarrhythmias.

Abstract P2-09-03: Spectrum, Prevalence and Clinical Outcomes of Germline Mutations in PALB2 Genes in 16501 Unselected BRCA1/2-negative Breast Cancer Patients: A Multi-Center Analysis

Use of comprehensive next-generation sequencing to identify pathogenic germline variants with therapeutic relevance in metastatic breast cancer.

Therapeutic Implications of Germline Testing in Patients With Advanced Cancers

Abstract PS10-04: The Landscape of Somatic Genetic Alterations in Breast Cancers from Carriers of Germline Pathogenic Variants in DNA-repair Genes

Abstract 977: Germline BRCA1/2 mutations detected by circulating tumor DNA testing in breast cancer patients: A retrospective mutiinstitutional analysis

Increased TP53 somatic evolution in peritoneal washes of individuals with BRCA1 germline mutations

Abstract P3-07-02: Identification of potential germline variants (GV) on tumor comprehensive genomic profiling (CGP) in patients with advanced breast cancer (BC): BRCA1/2 and beyond

DENSITY‐DEPENDENT SEXUAL SELECTION IN THE FUNGUS BEETLE, BOLITOTHERUS CORNUTUS

Abstract 5872: Investigation on the Prevalence of Germline and Somatic Mutations in Gynecological Malignancies: Implications for Risk Assessment and Therapeutic Decision-Making

Abstract PS16-08: Germline Mutation Landscape in Chinese Breast Cancer Patients

Perl Simulation of a Job Shop Type Problem

Identification and Characterization of Germline Pathogenic Variants Using Matched Tumor-Normal Next-Generation Sequencing in 7363 Pan-Cancer Patients in China

Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients.

Clinical and genetic characterization of cancer patients with multiple germline variants.

Effect of somatic-germline genomic integration on the contribution of pathogenic germline genetic variants (gPV) to colorectal cancer (CRC) carcinogenesis.

On the Heritability of Geographic Range Sizes

Clinical syndromes linked to biallelic germline variants in and

A Multi-Institutional Investigation Assessing Prevalence of Germline Genetic Alterations in Chinese Patients with Gastric Carcinoma.

Abstract P2-09-01: Population-based Risk Estimates of Clinical Subtypes of Breast Cancer among Carriers of Germline Pathogenic Variants in Cancer Predisposition Genes

Multigene Hereditary Cancer Panels Reveal High-Risk Pancreatic Cancer Susceptibility Genes.